[
  {
    "ts": null,
    "headline": "Top Novavax Shareholder Demands Company’s Sale",
    "summary": "Himanshu Shah, managing partner and chief investment officer at Shah Capital, slammed management, and said the company should sell itself.",
    "url": "https://finnhub.io/api/news?id=c1b99a395ced0a8bd4160d3bddfcc8d84c40df735d390f956f0f1e739ca5828a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760463180,
      "headline": "Top Novavax Shareholder Demands Company’s Sale",
      "id": 137085942,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Himanshu Shah, managing partner and chief investment officer at Shah Capital, slammed management, and said the company should sell itself.",
      "url": "https://finnhub.io/api/news?id=c1b99a395ced0a8bd4160d3bddfcc8d84c40df735d390f956f0f1e739ca5828a"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Roundup: Market Talk",
    "summary": "Find insight on Johnson & Johnson, Japanese pharmaceutical stocks and more in the latest Market Talks covering the health care sector.",
    "url": "https://finnhub.io/api/news?id=1ed07af1702230c5a3fa783602ed0410a687958784cb4b41b915cb257476179a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760460840,
      "headline": "Health Care Roundup: Market Talk",
      "id": 137085561,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Find insight on Johnson & Johnson, Japanese pharmaceutical stocks and more in the latest Market Talks covering the health care sector.",
      "url": "https://finnhub.io/api/news?id=1ed07af1702230c5a3fa783602ed0410a687958784cb4b41b915cb257476179a"
    }
  },
  {
    "ts": null,
    "headline": "5 Small Drug Stocks to Buy as the Industry Shows Some Recovery",
    "summary": "Innovation is at its peak in the Zacks Medical-Drugs industry. AKBA, IRWD, PYXS, CRDL and PSTV may prove to be good additions to one's portfolio.",
    "url": "https://finnhub.io/api/news?id=8173b8fd5fbe36f893a4658ec215d86285edf6652cdc57ae7d1653cf26cae89f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760453820,
      "headline": "5 Small Drug Stocks to Buy as the Industry Shows Some Recovery",
      "id": 137085944,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Innovation is at its peak in the Zacks Medical-Drugs industry. AKBA, IRWD, PYXS, CRDL and PSTV may prove to be good additions to one's portfolio.",
      "url": "https://finnhub.io/api/news?id=8173b8fd5fbe36f893a4658ec215d86285edf6652cdc57ae7d1653cf26cae89f"
    }
  },
  {
    "ts": null,
    "headline": "CorMedix Stock Plunges 16% in a Month: Should Investors Buy the Dip?",
    "summary": "CRMD shares slip 16%, but rising DefenCath sales and the Melinta deal can set the stage for renewed growth.",
    "url": "https://finnhub.io/api/news?id=cb3c304c46efc1a19f8e073272102dc2f8b93e689abfb08a555f2caff8461a2e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760452680,
      "headline": "CorMedix Stock Plunges 16% in a Month: Should Investors Buy the Dip?",
      "id": 137085945,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "CRMD shares slip 16%, but rising DefenCath sales and the Melinta deal can set the stage for renewed growth.",
      "url": "https://finnhub.io/api/news?id=cb3c304c46efc1a19f8e073272102dc2f8b93e689abfb08a555f2caff8461a2e"
    }
  },
  {
    "ts": null,
    "headline": "BMY Slips Below 50-Day SMA: Buy, Sell or Hold the Stock?",
    "summary": "Bristol Myers stock slips below its 50-day average as generic pressure, high debt, and trimmed earnings outlook weigh on sentiment",
    "url": "https://finnhub.io/api/news?id=7ea5c5af61855618f46bf786620e8351a6b6c0cbb6aba99b5a28b24ec7ca7fc2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760450460,
      "headline": "BMY Slips Below 50-Day SMA: Buy, Sell or Hold the Stock?",
      "id": 137085744,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Bristol Myers stock slips below its 50-day average as generic pressure, high debt, and trimmed earnings outlook weigh on sentiment",
      "url": "https://finnhub.io/api/news?id=7ea5c5af61855618f46bf786620e8351a6b6c0cbb6aba99b5a28b24ec7ca7fc2"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Earnings Beat Estimates. Why the Stock Is Dropping.",
    "summary": "Johnson & Johnson  reported better-than-expected earnings Tuesday, while announcing it would spin off a slower-growing division within its medical devices segment that makes hip and knee implants.  Now, Johnson & Johnson plans to separate that business into a new company that will operate under the name DePuy Synthes.  While sales for Johnson & Johnson’s medical devices division grew 5.6% on an operational basis between the third quarter of 2024 and the third quarter of 2025, orthopaedics sales grew more slowly, up just 2.4% over the same period.",
    "url": "https://finnhub.io/api/news?id=37f99b90fa6df76efe96e4bfb5786b7fb24f9c238e23a603857d0f7a40cf88bf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760445780,
      "headline": "Johnson & Johnson Earnings Beat Estimates. Why the Stock Is Dropping.",
      "id": 137085947,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Johnson & Johnson  reported better-than-expected earnings Tuesday, while announcing it would spin off a slower-growing division within its medical devices segment that makes hip and knee implants.  Now, Johnson & Johnson plans to separate that business into a new company that will operate under the name DePuy Synthes.  While sales for Johnson & Johnson’s medical devices division grew 5.6% on an operational basis between the third quarter of 2024 and the third quarter of 2025, orthopaedics sales grew more slowly, up just 2.4% over the same period.",
      "url": "https://finnhub.io/api/news?id=37f99b90fa6df76efe96e4bfb5786b7fb24f9c238e23a603857d0f7a40cf88bf"
    }
  },
  {
    "ts": null,
    "headline": "TUKYSA Combination Significantly Improves Progression-Free Survival as First-Line Maintenance in HER2+ Metastatic Breast Cancer in HER2CLIMB-05 Trial",
    "summary": "NEW YORK, October 14, 2025--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 HER2CLIMB-05 trial of first-line combination therapy with the tyrosine kinase inhibitor TUKYSA® (tucatinib) in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). HER2CLIMB-05 is evaluating TUKYSA versus placebo, both in combination with first-line standard-of-care maintenance therapy (trastuzumab plus pertuzumab) following chemotherapy",
    "url": "https://finnhub.io/api/news?id=9826dc126951168b18748135b073c3aa1ddd7c81a7183044f0a91bb0b59f93d5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760438700,
      "headline": "TUKYSA Combination Significantly Improves Progression-Free Survival as First-Line Maintenance in HER2+ Metastatic Breast Cancer in HER2CLIMB-05 Trial",
      "id": 137085948,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK, October 14, 2025--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 HER2CLIMB-05 trial of first-line combination therapy with the tyrosine kinase inhibitor TUKYSA® (tucatinib) in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). HER2CLIMB-05 is evaluating TUKYSA versus placebo, both in combination with first-line standard-of-care maintenance therapy (trastuzumab plus pertuzumab) following chemotherapy",
      "url": "https://finnhub.io/api/news?id=9826dc126951168b18748135b073c3aa1ddd7c81a7183044f0a91bb0b59f93d5"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer’s (PFE) Pipeline and Dividend Yield Make it a Compelling Income Stock",
    "summary": "Pfizer Inc. (NYSE:PFE) is included among the 12 Best Dividend Stocks with Yields Above 4%. Pfizer Inc. (NYSE:PFE) is a‌ major US pharmaceutical and biotech‍n‍ology company that‌ offers a wide rang‌e⁠ o‌f products and services. In rec‌ent years, the company has experienced declini‍ng rev​e‌nue and profits, leading t⁠o a signific⁠an‍t d‌r⁠op in i‌ts‌ market value. […]",
    "url": "https://finnhub.io/api/news?id=c23b97ff70e5f2c2dde985a1255778a026cc64a844acfa09ea667862176f8aef",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760411811,
      "headline": "Pfizer’s (PFE) Pipeline and Dividend Yield Make it a Compelling Income Stock",
      "id": 137074438,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) is included among the 12 Best Dividend Stocks with Yields Above 4%. Pfizer Inc. (NYSE:PFE) is a‌ major US pharmaceutical and biotech‍n‍ology company that‌ offers a wide rang‌e⁠ o‌f products and services. In rec‌ent years, the company has experienced declini‍ng rev​e‌nue and profits, leading t⁠o a signific⁠an‍t d‌r⁠op in i‌ts‌ market value. […]",
      "url": "https://finnhub.io/api/news?id=c23b97ff70e5f2c2dde985a1255778a026cc64a844acfa09ea667862176f8aef"
    }
  }
]